Compare FTCI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | KZIA |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 100.8M |
| IPO Year | 2021 | 2002 |
| Metric | FTCI | KZIA |
|---|---|---|
| Price | $4.37 | $11.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $10.80 | ★ $19.50 |
| AVG Volume (30 Days) | 193.1K | ★ 228.4K |
| Earning Date | 05-01-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $65.44 | N/A |
| Revenue Next Year | $45.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $3.21 | $3.30 |
| 52 Week High | $12.75 | $17.40 |
| Indicator | FTCI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 45.98 | 48.35 |
| Support Level | $3.30 | $5.71 |
| Resistance Level | $5.31 | $14.82 |
| Average True Range (ATR) | 0.54 | 1.05 |
| MACD | 0.01 | -0.31 |
| Stochastic Oscillator | 50.36 | 8.31 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.